Clinical development of a novel inactivated poliomyelitis vaccine based on attenuated Sabin poliovirus strains

• Published in: Expert review of vaccines Vol. 10; no. 5; pp. 635 - 644
• Main Authors: Verdijk, Pauline, Rots, Nynke Y, Bakker, Wilfried AM
• Format: Journal Article
• Language: English
• Published: England Taylor & Francis 01.05.2011; Expert Reviews Ltd; Informa Healthcare
• Subjects: Animal experimentation; Biomedical Research - trends; clinical trial; Clinical trials; Clinical Trials as Topic; Humans; inactivated poliomyelitis vaccine; polio eradication; Poliomyelitis; Poliomyelitis - immunology; Poliomyelitis - prevention & control; Poliomyelitis vaccine; Poliovirus; Poliovirus Vaccine, Inactivated - economics; Poliovirus Vaccine, Inactivated - immunology; Poliovirus Vaccine, Oral - immunology; Prevention; Product development; Reviews; Sabin-IPV; vaccine development; Vaccines
• ISSN: 1476-0584; 1744-8395
• DOI: 10.1586/erv.11.51

Following achievement of polio eradication, the routine use of all live-attenuated oral poliovirus vaccines should be discontinued. However, the costs per vaccine dose for the alternative inactivated poliovirus vaccine (IPV) are significantly higher and the current production capacity is not sufficient for worldwide distribution of the vaccine. In order to achieve cost-prize reduction and improve affordability, IPV production processes and dose-sparing strategies should be developed to facilitate local manufacture at a relatively lower cost. The use of attenuated Sabin instead of wild-type polio strains will provide additional safety during vaccine production and permits production in low-cost settings. Sabin-IPV is under development by several manufacturers. This article gives an overview of results from clinical trials with Sabin-IPV and discusses the requirements and challenges in the clinical development of this novel IPV.